Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

0.8500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231,298
Open 0.8500
Bid (Size) 0.8110 (2)
Ask (Size) 0.8200 (18)
Prev. Close 0.8500
Today's Range 0.8500 - 0.8500
52wk Range 0.4100 - 1.779
Shares Outstanding 21,588,756
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+2.41%
+2.41%
1 Month
+20.98%
+20.98%
3 Month
+18.35%
+18.35%
6 Month
+86.00%
+86.00%
1 Year
-10.62%
-10.62%

More News

Read More
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma: Q4 Earnings Insights
Via Benzinga
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Via Benzinga
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
From HOOKIPA Pharma Inc.
Via GlobeNewswire
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
Via Benzinga
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Nasdaq Gains 100 Points; CarMax Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; Micron Issues Strong Forecast
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.